SCHEMBL7670801

SCHEMBL7670801

CCc1ccc(C(=O)Nc2ccc(S(=O)(=O)NCC(=O)OC(C)(C)C)cc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.52
ALDH1A1 P00352 3/20 0.52
F2 P00734 1/20 0.49
TMPRSS6 Q8IU80 1/20 0.49
SMN1; SMN2 Q16637 4/20 0.47
KDM4E B2RXH2 1/20 0.47
NPC1 O15118 1/20 0.47
GAA P10253 1/20 0.47
HPGD P15428 1/20 0.47
RAB9A P51151 1/20 0.47
MAPK1 P28482 1/20 0.47
KCNA5 P22460 1/20 0.46
GHSR Q92847 1/20 0.46
MAPT P10636 3/20 0.46
SLC2A1 P11166 1/20 0.45
NAMPT P43490 1/20 0.45
PRMT1 Q99873 2/20 0.45
STAT3 P40763 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7674292 0.91 ENPP1 (0.54) LMNAALDH1A1F2TMPRSS6SMN1; SMN2
SCHEMBL7667916 0.90 F2 (0.52) LMNAALDH1A1F2TMPRSS6SMN1; SMN2
SCHEMBL5092484 0.89 MEN1 (0.55) LMNAALDH1A1F2TMPRSS6SMN1; SMN2
SCHEMBL7667880 0.89 LMNA (0.54) LMNAALDH1A1F2TMPRSS6SMN1; SMN2
SCHEMBL7669959 0.89 KDM4E (0.53) LMNAALDH1A1SMN1; SMN2KDM4ENPC1
SCHEMBL7670379 0.88 ALDH1A1 (0.50) LMNAALDH1A1F2TMPRSS6SMN1; SMN2
SCHEMBL7671606 0.88 KDM4E (0.52) LMNAALDH1A1SMN1; SMN2KDM4ENPC1
SCHEMBL7673461 0.88 KDM4E (0.52) LMNAALDH1A1SMN1; SMN2KDM4ENPC1
SCHEMBL7669245 0.88 KDM4E (0.52) LMNAALDH1A1SMN1; SMN2KDM4ENPC1
SCHEMBL7671859 0.88 PRMT1 (0.56) LMNAALDH1A1F2TMPRSS6SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6403644-B1 FOR PREVENTION AND/OR TREATMENT OF DISEASES INDUCED BY OVEREXPRESSION AND EXCESS ACTIVITY OF MATRIX METALLOPROTEINASE; FOR EXAMPLE, RHEUMATOID, ARTHROSTEITIS, UNUSUAL BONE RESORPTION, OSTEOPOROSIS, PERIODONTITIS ONO PHARMACEUTICAL CO., LTD. (JP) 2002-06-11 US disclosed
US-6177466-B1 Sulfonylamino acid derivatives ONO PHARMACEUTICAL CO., LTD. (JP) 2001-01-23 US disclosed
EP-0757037-A2 Sulfonylamino acid derivatives as metalloproteinase inhibitors ONO PHARMACEUTICAL CO., LTD. (JP) 1997-02-05 EP disclosed